Springer Nature AG (SPGNY) Fair Value & Analysis
Communication Services · US · Market cap $2.3B
Analysis
Springer Nature AG (SPGNY) currently trades at $11.36, while our model-based Fair Value estimate is $34.69 — implying the stock looks roughly 205.4% undervalued today. We read business quality at 87/100 (high quality), in the Communication Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Springer Nature AG & Co. KGaA, together with its subsidiaries, engages in the publishing business in Germany, the United Kingdom, the United States, and internationally. The company operates through three segments: Research, Education, and Health. It offers journals across various academic disciplines under the Nature Portfolio and Springer brand names; books in print and digital formats across various scientific disciplines, including monographs, textbooks, conference proceedings, handbook series, reference works, and briefs under the Springer and Palgrave Macmillan brand names; and support services to researchers, institutions, and industry professionals with AI-powered tools and services, such as AdisInsight, Springer Nature Experiments, protocols.io, and SpringerMaterials, as well as professional development and career services under the Nature Masterclasses, Nature Careers, and Nature Conferences brand names. The company also provides English language teaching content and natio…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.